Pfizer, Moderna COVID-19 Boosters Effectiveness Wanes After Four Months: CDC Study

COVID-19 vaccine boosters from Pfizer Inc PFEBioNTech SE BNTX and Moderna Inc MRNA become less effective after four months but still provide significant protection against hospitalization, a CDC study found.

  • While vaccine efficacy was still strong two months after a booster shot, it declined significantly after four months.
  • Efficacy against COVID-19–associated emergency department visits and hospitalization was 87% and 91%, respectively, during the two months after a third dose and decreased to 66% and 78% by the fourth month after a third dose. 
  • Related: Menstrual Irregularities Cases After mRNA COVID-19 Vaccine - EMA Reviews Cases.
  • Protection against hospitalizations exceeded that against emergency department visits.
  • Researchers said the results suggest that additional boosters may be needed.
  • "The finding that protection conferred by mRNA vaccines waned in the months after receipt of a third vaccine dose reinforces the importance of further consideration of additional doses to sustain or improve protection against COVID-19–associated ED/UC encounters and COVID-19 hospitalizations," CDC wrote.
  • Price Action: MRNA shares are down 12.1% at $141.84, PFE stock is down 2.86% at $49.33, and BNTX shares are down 8.59% at $156.27 during the market session on the last check Monday.
BNTX Logo
BNTXBioNTech SE
$120.544.97%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
78.35
Growth
-
Quality
-
Value
54.07
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...